Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 14Thoracic 6Gynecologic 6Genitourinary 5Gastrointestinal 4Sarcoma 3Dermatologic 3Head & Neck 2Plasma cell 1Other solid neoplasm 1Endocrine 1CNS 1

Conditions

Sarcoma 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Urogenital Neoplasms 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Squamous Cell 1Multiple Myeloma 1Microsatellite Instability 1Mesothelioma 1Histiocytoma, Malignant Fibrous 1Giant Cell Tumor of Bone 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

Nivolumab 2spartalizumab 1regorafenib 1fludarabine 1aldesleukin 1Ipilimumab 1IPI-549 1Cyclophosphamide 1Clinical Trials, Phase II as Topic 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × fludarabine × Endocrine × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡